All News
Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#2033 How negative is sero-ve #Sjogren? A study discovered new autoantibodies using Peptidome Array Technology. AUC for these 8 peptides was excellent 0.97. Mainly in White/Hispanic. Need validation in other groups and association with other markers/biopsy @RheumNow https://t.co/xAFrjK9mS3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Urine Proteomics in SLE with Dr. Michelle Petri
Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22.
https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Year in Review | Presented by Dr. Carol Langford at #ACR22
🌟 Review the Most Important Clinical Research Studies in the Past Year in #Rheumatology! 💫 https://t.co/Ao11xX1bYt
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4
Janet Pope Janetbirdope ( View Tweet)
#ACRBest Abstracts - Day 2
Day two at #ACR22 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for today.
https://t.co/lAG1v2dHKQ https://t.co/oAG6zE7QzX
Links:
Dr. John Cush RheumNow ( View Tweet)
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Most VEXAS pts have pulm involvement on HRCT. Pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement. Abs 1569 #ACR22 @RheumNow https://t.co/7AB3b9e7Lt https://t.co/ikhQMEu5GA
Dr. Rachel Tate uptoTate ( View Tweet)
Sarilumab demonstrated efficacy in difficult to treat GC resistant PMR patients. Abs 1543 #ACR22 @RheumNow https://t.co/TCo5g5i1qh https://t.co/tZOhvvuhpY
Dr. Rachel Tate uptoTate ( View Tweet)
Does lifestyle impact Tx. response?
#Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA
- The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi
- Important to discuss lifestyle when starting tx.
@RheumNow #ACR22 https://t.co/z98DFMLxu3
Akhil Sood MD AkhilSoodMD ( View Tweet)
Refractory cystoid macular edema assoc'd w/ Bechet's uveitis can be effectively treated either with ADA, IFX or TCZ. Abs 1564 #ACR22 @RheumNow https://t.co/WcEI4d0Cl5 https://t.co/Tk0T41coog
Dr. Rachel Tate uptoTate ( View Tweet)
ACR2022 Topic Panels https://t.co/0cto8DE7P5
Dr. John Cush RheumNow ( View Tweet)
Industry Abstract Previews of #ACR22
The pharmaceutical companies will showcase their featured clinical trials and abstracts at #ACR22. These are their best studies for you to review and evaluate as part of your to-do list.
https://t.co/8fBJmT1cXG https://t.co/r7H5sqELPo
Links:
Dr. John Cush RheumNow ( View Tweet)
Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd
Dr. Rachel Tate uptoTate ( View Tweet)
ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN
Dr. Rachel Tate uptoTate ( View Tweet)
#Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional impairment using PSOAS cohort
- identified 5 clusters based on comorbidity
- Depression cluster --> ↑ disease activity and fxnl impairment
@RheumNow #ACR22 https://t.co/cGz4vpOGJ9
Akhil Sood MD AkhilSoodMD ( View Tweet)
Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. Abs 1319 #ACR22 @RheumNow https://t.co/xbYW9y522I https://t.co/QQVjVXoFNf
Dr. Rachel Tate uptoTate ( View Tweet)
Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP. @RheumNow https://t.co/VMkUnwWt4v https://t.co/fTRPo25GZm
Dr. Rachel Tate uptoTate ( View Tweet)
PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ
Dr. Rachel Tate uptoTate ( View Tweet)